Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?

European Journal of Pharmacology

Volumn 614, Issue 1-3, 2009, Pages 146-152

  Halici, Zekai ^a   Bilen, Habip ^a   Albayrak, Fatih ^a   Uyanik, Abdullah ^a   Cetinkaya, Ramazan ^a   Suleyman, Halis ^a   Keles, Osman Nuri ^a   Unal, Bunyami ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

Angiotensin; Diabetes mellitus; Liver; Stereology; TGF

Indexed keywords

SODIUM CHLORIDE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA;

ALLOXAN DIABETES MELLITUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL; LIVER FIBROSIS; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STELLATE CELL; TREATMENT DURATION;

ALLOXAN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, EXPERIMENTAL; FIBROSIS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICROSCOPY, ELECTRON; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA;

EID: 67349204348     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.042     Document Type: Article

References (54)

1. Adler M., Verset C., and Moreno G. How to prevent complications of liver cirrhosis?. Revue Médicale de Bruxelles 28 (2007) 270-275
2. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes/Metabolism Research and Reviews 18 (2002) S5-S9
3. Arroyo V., Bosch J., Mauri M., Ribera F., Navarro-Lopez F., and Rodes J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. European Journal of Clinical Investigation 11 (1981) 221-229
4. Bataller R., Gines P., Nicolas J.M., Gorbig M.N., Garcia-Ramallo E., Gasull X., Bosch J., Arroyo V., and Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118 (2000) 1149-1156
5. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
6. Bloch M.J., and Basile J. Analysis of recent papers in hypertension. Journal of Clinical Hypertension (Greenwich, Conn.) 6 (2004) 466-468
7. Brock R.W., and Dorman R.B. Obesity, insulin resistance and hepatic perfusion. Microcirculation 14 (2007) 339-347
8. Campbell D.J. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of rat. The Journal of Clinical Investigation 78 (1986) 31-39
9. Campbelli D.J. Circulating and tissue angiotensin systems. The Journal of Clinical Investigation 79 (1987) 1-6
10. Cianchetti S., Del Fiorentino A., Colognato R., Di Stefano R., Franzoni F., and Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 22 (2007) (Electornic publication ahead of print)
11. De Gasparo M. Angiotensin II and nitric oxide interactions. Heart Failure Reviews 7 (2002) 347-358
12. De Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger H. The angiotensin II receptors. Pharmacological Reviews 52 (2000) 415-472
13. Dorph-Petersen K.A., Pierri J.N., Sun Z., Sampson A.R., and Lewis D.A. Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. The Journal of Comparative Neurology 472 (2004) 449-462
14. Dzau V.J., Gibbons G.H., and Pratt R.E. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 18 II (1991) 100-105
15. Folli F., Kahn C.R., Hansen H., Bouchie J.L., and Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. The Journal of Clinical Investigation 100 (1997) 2158-2169
16. Friedman S.L. The virtuosity of hepatic stellate cells. Gastroenterology 117 (1999) 1244-1246
17. Gressner A.M., and Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. Journal of Cellular and Molecular Medicine 10 (2006) 76-99
18. Gressner O.A., Weiskirchen R., and Gressner A.M. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comparative Hepatology 30 (2007) 6-7
19. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
20. Gujral J.S., Hinson J.A., and Jaeschke H. Chlorotyrosine protein adducts are reliable biomarkers of neutrophil-induced cytotoxicity in vivo. Comparative Hepatology 3 (2004) S1-S48
21. Gundersen H.J., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. Journal of Microscopy 147 (1987) 229-263
22. Gundersen H.J.G., Jensen E.B.V., Kiêu K., and Nielsen J. The efficiency of systematic sampling in stereology - reconsidered. Journal of Microscopy 193 (1999) 199-211
23. Gupta S.S. Prospects and perspectives of natural plant products in medicine. Indian Journal of Pharmacology 26 (1994) 1-12
24. Howard C.V., and Reed M.G. Unbiased stereology: three dimensional measurement in microscopy (1998), Bios Scientific Publishers, Oxford 1-37
25. Kaplan S., Canan S., Aslan H., Unal B., and Sahin B. A simple technique to measure the movements of the microscope stage along the x and y axes for stereological methods. Journal of Microscopy 203 (2001) 321-325
26. Kurtz T.W., and Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. Journal of Hypertension 22 (2004) 2253-2261
27. Leung P.S., and Carlsson P.O. Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. Journal of Molecular Endocrinology 26 (2001) 155-164
28. Leung P.S., Fung M.L., and Sernia C. Chronic hypoxia induced down-regulation of angiotensinogen expression in rat epididymis. Regulatory Peptides 96 (2001) 143-149
29. Leung P.S., Lam S.Y., and Fung M.L. Chronic hypoxia upregulates the expression and function of AT1 receptor in rat carotid body. Journal of Endocrinology 167 (2000) 517-524
30. Leung P.S., Suen P.M., Ip S.P., Yip C.K., Chen G., and Lai P.B. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regulatory Peptides 116 (2003) 61-69
31. Marcos R., Rocha E., Henrique R.M.F., and Monteiro R.A.F. A New approach to an unbiased estimate of the hepatic stellate cell index in the rat liver: an example in healthy conditions. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 51 (2003) 1101-1104
32. Mattfeldt T., Mall G., Gharehbaghi H., and Möller P. Estimation of surface area and length with the orientator. Journal of Microscopy 159 (1990) 301-317
33. Michael M.D., and Ruderman N.B. Insulin and other growth factors. In: Arias I.M., Boyer J.L., Chisari F.V., Fausto N., Schachter D., and Shafritz D.A. (Eds). The liver: biology and pathobiology (2001), Lippincott Williams & Wilkins, Philadelphia 511-523
34. Miura Y., Yamamoto N., Tsunekawa S., Taguchi S., Eguchi Y., Ozaki N., and Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28 (2005) 757-758
35. Nyengaard J.R., and Gundersen H.J.G. The isector: a simple and direct method for generating isotropic, uniform random sections from small specimens. Journal of Microscopy 165 (1992) 427-431
36. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujishiro M., Katagiri H., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Komuro I., and Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 (2002) 872-879
37. Ohishi T., Saito H., Tsusaka K., Toda K., Inagaki H., Hamada Y., Kumagai N., Atsukawa K., and Ishii H. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic arbontetrachloride-induced hepatic fibrosis in rats. Hepatology Research: the Official Journal of the Japan Society of Hepatology 21 (2001) 147-158
38. Paizis G., Gilbert R.E., Cooper M.E., Murthi P., Schembri J.M., Wu L.L., Rumble J.R., Kelly D.J., Tikellis C., Cox A., Smallwood R.A., and Angus P.W. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. Journal of Hepatology 35 (2001) 376-385
39. Paolisso G., Tagliamonte M.R., Gambardella A., Manzella D., Gualdiero P., Varricchio G., Verza M., and Varricchio M. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. Journal of Human Hypertension 11 (1997) 307-312
40. Prow T.W., Bhutto I., Grebe R., Uno K., Merges C., McLeod D.S., and Lutty G.A. Nanoparticle-delivered biosensor for reactive oxygen species in diabetes. Vision Research 48 (2008) 478-485
41. Rockey D.C., and Weisiger R.A. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 24 (1996) 233-240
42. Roth S., Michel K., and Gressner A.M. (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology 27 (1998) 1003-1012
43. Saleh J., Sniderman A.D., and Cianflone K. Regulation of plasma fatty acid metabolism. Clinica Chimica Acta; International Journal of Clinical Chemistry 286 (1999) 163-180
44. Schäfer A., Flierl U., Vogt C., Menninger S., Tas P., Ertl G., and Bauersachs J. Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus. Pharmacological Research: the Official Journal of the Italian Pharmacological Society 56 (2007) 217-223
45. Schneider A.W., Kalk J.F., and Klein C.P. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 29 (1999) 334-339
46. Schuppan D., Ruehl M., Somasundaram R., and Hahn E.G. Matrix as a modulator of hepatic fibrogenesis. Seminars in Liver Disease 21 (2001) 351-372
47. Souza L., Barreto F., Gomes da Silva E., Andrades M.E., Machado Guimarães E.L., Behr G.A., Moreira J.C., and Bernard E.A. Regulation of LPS stimulated ROS production in peritoneal macrophages from alloxan-induced diabetic rats: involvement of high glucose and PPARγ. Life Sciences 81 (2007) 153-159
48. Takahashi T., Ono H., Ono Y., Ishimitsu T., and Matsuoka H. Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease inTGF-beta(1). International Heart Journal 48 (2007) 637-647
49. Van Guilder G.P., Hoetzer G.L., Greiner J.J., Stauffer B.L., and Desouza C.A. Metabolic syndrome and endothelial fibrinolytic capacity in obese adults. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 294 (2008) 39-44
50. Velloso L.A., Folli F., Sun X.J., White M.F., Saad M.J., and Kahn C.R. Cross-talk between the insulin and angiotensin signaling systems. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 12490-12495
51. Waeber B., and Feihl F. Stratification of global cardiovascular risk according to the ESH/ESC guidelines. Revue médicale Suisse 3 (2007) 1992-1994
52. Wang Y.J., Sun Z.Q., Quan Q.Z., and Yu J.J. Fat-storing cells and liver fibrosis. China national Journal of New Gastroenterology = Zhongguo Xin Xiao Hua Bing Xue Za Zhi 2 (1996) 58-60
53. Yang S., Lin H.Z., Hwang J., Chacko V.P., and Diehl A.M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?. Cancer Research 61 (2001) 5016-5023
54. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., Hasegawa T., Tokusashi Y., Miyokawa N., and Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225